Review ArticleReview
Open Access

Intricate roles of estrogen and estrogen receptors in digestive system cancers: a systematic review

Xiaoning Gan, Guanqi Dai, Yonghao Li, Lin Xu and Guolong Liu
Cancer Biology & Medicine October 2024, 21 (10) 898-915; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0224

References

  1. 1.↵
    2. Sung H,
    3. Ferlay J,
    4. Siegel RL,
    5. Laversanne M,
    6. Soerjomataram I,
    7. Jemal A, et al.
    Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209–49.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Mauvais-Jarvis F,
    3. Bairey Merz N,
    4. Barnes PJ,
    5. Brinton RD,
    6. Carrero JJ,
    7. DeMeo DL, et al.
    Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020; 396: 565–82.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Clocchiatti A,
    3. Cora E,
    4. Zhang Y,
    5. Dotto GP.
    Sexual dimorphism in cancer. Nat Rev Cancer. 2016; 16: 330–9.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. He Y,
    3. Su Y,
    4. Zeng J,
    5. Chong W,
    6. Hu X,
    7. Zhang Y, et al.
    Cancer-specific survival after diagnosis in men versus women: a pan-cancer analysis. MedComm (2020). 2022; 3: e145.
  5. 5.↵
    2. Abou-Ismail MY,
    3. Citla Sridhar D,
    4. Nayak L.
    Estrogen and thrombosis: a bench to bedside review. Thromb Res. 2020; 192: 40–51.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Santen RJ,
    3. Simpson E.
    History of estrogen: its purification, structure, synthesis, biologic actions, and clinical implications. Endocrinology. 2019; 160: 605–25.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Fuentes N,
    3. Silveyra P.
    Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019; 116: 135–70.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Ur Rahman MS,
    3. Cao J.
    Estrogen receptors in gastric cancer: advances and perspectives. World J Gastroenterol. 2016; 22: 2475–82.
    OpenUrlPubMed
  9. 9.↵
    2. Flouriot G,
    3. Brand H,
    4. Denger S,
    5. Metivier R,
    6. Kos M,
    7. Reid G, et al.
    Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J. 2000; 19: 4688–700.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Yasar P,
    3. Ayaz G,
    4. User SD,
    5. Gupur G,
    6. Muyan M.
    Molecular mechanism of estrogen-estrogen receptor signaling. Reprod Med Biol. 2017; 16: 4–20.
    OpenUrlPubMed
  11. 11.↵
    2. Wang Z,
    3. Zhang X,
    4. Shen P,
    5. Loggie BW,
    6. Chang Y,
    7. Deuel TF.
    Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun. 2005; 336: 1023–7.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    2. Pagano MT,
    3. Ortona E,
    4. Dupuis ML.
    A role for estrogen receptor alpha36 in cancer progression. Front Endocrinol (Lausanne). 2020; 11: 506.
    OpenUrlPubMed
  13. 13.↵
    2. Revankar CM,
    3. Cimino DF,
    4. Sklar LA,
    5. Arterburn JB,
    6. Prossnitz ER.
    A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005; 307: 1625–30.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    2. Barton M,
    3. Filardo EJ,
    4. Lolait SJ,
    5. Thomas P,
    6. Maggiolini M,
    7. Prossnitz ER.
    Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives. J Steroid Biochem Mol Biol. 2018; 176: 4–15.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Guo Y,
    3. Wu G,
    4. Yi J,
    5. Yang Q,
    6. Jiang W,
    7. Lin S, et al.
    Anti-hepatocellular carcinoma effect and molecular mechanism of the estrogen signaling pathway. Front Oncol. 2021; 11: 763539.
  16. 16.↵
    2. Marino M,
    3. Galluzzo P,
    4. Ascenzi P.
    Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics. 2006; 7: 497–508.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    2. Zhao Y,
    3. Li Z.
    Interplay of estrogen receptors and FOXA factors in the liver cancer. Mol Cell Endocrinol. 2015; 418 Pt 3: 334–9.
    OpenUrlPubMed
  18. 18.↵
    2. Vrtačnik P,
    3. Ostanek B,
    4. Mencej-Bedrač S,
    5. Marc J.
    The many faces of estrogen signaling. Biochem Med (Zagreb). 2014; 24: 329–42.
    OpenUrlPubMed
  19. 19.↵
    2. Hewitt SC,
    3. Korach KS.
    Estrogen receptors: new directions in the new millennium. Endocr Rev. 2018; 39: 664–75.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Zhang Y,
    3. Ren JS,
    4. Shi JF,
    5. Li N,
    6. Wang YT,
    7. Qu C, et al.
    International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer. 2015; 15: 94.
    OpenUrlPubMed
  21. 21.↵
    2. Kur P,
    3. Kolasa-Wołosiuk A,
    4. Misiakiewicz-Has K,
    5. Wiszniewska B.
    Sex hormone-dependent physiology and diseases of liver. Int J Environ Res Public Health. 2020; 17: 2620.
    OpenUrlPubMed
  22. 22.↵
    2. Keng VW,
    3. Largaespada DA,
    4. Villanueva A.
    Why men are at higher risk for hepatocellular carcinoma? J Hepatol. 2012; 57: 453–4.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Li Z,
    3. Tuteja G,
    4. Schug J,
    5. Kaestner KH.
    Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell. 2012; 148: 72–83.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    2. O’Brien MH,
    3. Pitot HC,
    4. Chung SH,
    5. Lambert PF,
    6. Drinkwater NR,
    7. Bilger A.
    Estrogen receptor-α suppresses liver carcinogenesis and establishes sex-specific gene expression. Cancers (Basel). 2021; 13: 2355.
    OpenUrlPubMed
  25. 25.↵
    2. Schmidt-Arras D,
    3. Rose-John S.
    IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016; 64: 1403–15.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Bergmann J,
    3. Müller M,
    4. Baumann N,
    5. Reichert M,
    6. Heneweer C,
    7. Bolik J, et al.
    IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. Hepatology. 2017; 65: 89–103.
    OpenUrlCrossRefPubMed
  27. 27.↵
    2. Lokau J,
    3. Schoeder V,
    4. Haybaeck J,
    5. Garbers C.
    Jak-stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma. Cancers (Basel). 2019; 11: 1704.
    OpenUrlPubMed
  28. 28.↵
    2. Naugler WE,
    3. Sakurai T,
    4. Kim S,
    5. Maeda S,
    6. Kim K,
    7. Elsharkawy AM, et al.
    Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007; 317: 121–4.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    2. Montella M,
    3. D’Arena G,
    4. Crispo A,
    5. Capunzo M,
    6. Nocerino F,
    7. Grimaldi M, et al.
    Role of sex hormones in the development and progression of hepatitis B virus-associated hepatocellular carcinoma. Int J Endocrinol. 2015; 2015: 854530.
  30. 30.↵
    2. Zheng B,
    3. Zhu YJ,
    4. Wang HY,
    5. Chen L.
    Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. Sci China Life Sci. 2017; 60: 575–84.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Wang SH,
    3. Yeh SH,
    4. Lin WH,
    5. Yeh KH,
    6. Yuan Q,
    7. Xia NS, et al.
    Estrogen receptor α represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4α. Gastroenterology. 2012; 142: 989–98.e4.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Lee S,
    3. Lee M,
    4. Kim JB,
    5. Jo A,
    6. Cho EJ,
    7. Yu SJ, et al.
    17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling. Biochem Biophys Res Commun. 2016; 473: 1247–54.
    OpenUrlPubMed
  33. 33.↵
    2. Hassan MM,
    3. Botrus G,
    4. Abdel-Wahab R,
    5. Wolff RA,
    6. Li D,
    7. Tweardy D, et al.
    Estrogen replacement reduces risk and increases survival times of women with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2017; 15: 1791–9.
    OpenUrlPubMed
  34. 34.↵
    2. Haring MPD,
    3. Gouw ASH,
    4. de Haas RJ,
    5. Cuperus FJC,
    6. de Jong KP,
    7. de Meijer VE.
    The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: a retrospective cohort study. Liver Int. 2019; 39: 905–13.
    OpenUrlPubMed
  35. 35.↵
    2. Williams DS.
    Hepatic Adenoma. J Insur Med. 2020; 48: 165–7.
    OpenUrl
  36. 36.↵
    2. Wang M,
    3. Sarkar M,
    4. Mehta N.
    Now you see it, now you don’t: estrogen exposure and obesity effects on HCA development and regression. Hepatology. 2023; 77: 341–43.
    OpenUrlPubMed
  37. 37.↵
    2. Thevathasan T,
    3. Colbatzky T,
    4. Schmelzle M,
    5. Pratschke J,
    6. Krenzien F.
    Risk factors for malignant transformation of hepatocellular adenoma to hepatocellular carcinoma: protocol for systematic review and meta-analysis. BMJ Open. 2021; 11: e045733.
  38. 38.↵
    2. Stoot JH,
    3. Coelen RJ,
    4. De Jong MC,
    5. Dejong CH.
    Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010; 12: 509–22.
    OpenUrlCrossRefPubMed
  39. 39.↵
    2. Ponnatapura J,
    3. Kielar A,
    4. Burke LMB,
    5. Lockhart ME,
    6. Abualruz AR,
    7. Tappouni R, et al.
    Hepatic complications of oral contraceptive pills and estrogen on MRI: controversies and update – adenoma and beyond. Magn Reson Imaging. 2019; 60: 110–21.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Nault JC,
    3. Couchy G,
    4. Balabaud C,
    5. Morcrette G,
    6. Caruso S,
    7. Blanc JF, et al.
    Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017; 152: 880–94.e6.
    OpenUrlCrossRefPubMed
  41. 41.↵
    2. Villemain L,
    3. Prigent S,
    4. Abou-Lovergne A,
    5. Pelletier L,
    6. Chiral M,
    7. Pontoglio M, et al.
    Sigma 1 receptor is overexpressed in hepatocellular adenoma: involvement of ERalpha and HNF1alpha. Cancers (Basel). 2020; 12: 2213.
    OpenUrlPubMed
  42. 42.↵
    2. Bucurica S,
    3. Lupanciuc M,
    4. Ionita-Radu F,
    5. Stefan I,
    6. Munteanu AE,
    7. Anghel D, et al.
    Estrobolome and hepatocellular adenomas-connecting the dots of the gut microbial beta-glucuronidase pathway as a metabolic link. Int J Mol Sci. 2023; 24: 16034.
  43. 43.↵
    2. Huang S,
    3. Wang W,
    4. Cheng Y,
    5. Lin J,
    6. Wang M.
    Clinicopathological and prognostic significance of klotho and estrogen receptors expression in human hepatocellular carcinoma. Turk J Gastroenterol. 2021; 32: 828–36.
    OpenUrlPubMed
  44. 44.↵
    2. Jeon Y,
    3. Yoo JE,
    4. Rhee H,
    5. Il Kim G,
    6. Chung T,
    7. Yoon S, et al.
    YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior. Exp Mol Med. 2021; 53: 1055–67.
    OpenUrlPubMed
  45. 45.↵
    2. Bhat M,
    3. Pasini E,
    4. Pastrello C,
    5. Angeli M,
    6. Baciu C,
    7. Abovsky M, et al.
    Estrogen receptor 1 inhibition of Wnt/β-catenin signaling contributes to sex differences in hepatocarcinogenesis. Front Oncol. 2021; 11: 777834.
  46. 46.↵
    2. Lu Y,
    3. Tian N,
    4. Hu L,
    5. Meng J,
    6. Feng M,
    7. Zhu Y, et al.
    ERα down-regulates carbohydrate responsive element binding protein and decreases aerobic glycolysis in liver cancer cells. J Cell Mol Med. 2021; 25: 3427–36.
    OpenUrlPubMed
  47. 47.↵
    2. Tu CC,
    3. Kumar VB,
    4. Day CH,
    5. Kuo WW,
    6. Yeh SP,
    7. Chen RJ, et al.
    Estrogen receptor α (ESR1) over-expression mediated apoptosis in Hep3B cells by binding with SP1 proteins. J Mol Endocrinol. 2013; 51: 203–12.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    2. Guo Y,
    3. Cai X,
    4. Lu H,
    5. Li Q,
    6. Zheng Y,
    7. Lin Z, et al.
    17β-estradiol promotes apoptosis of HepG2 cells caused by oxidative stress by increasing Foxo3a phosphorylation. Front Pharmacol. 2021; 12: 607379.
  49. 49.↵
    2. Xiao Y,
    3. Liu G,
    4. Sun Y,
    5. Gao Y,
    6. Ouyang X,
    7. Chang C, et al.
    Targeting the estrogen receptor alpha (ERα)-mediated circ-SMG1.72/miR-141-3p/gelsolin signaling to better suppress the HCC cell invasion. Oncogene. 2020; 39: 2493–508.
    OpenUrlPubMed
  50. 50.↵
    2. Yang W,
    3. Lu Y,
    4. Xu Y,
    5. Xu L,
    6. Zheng W,
    7. Wu Y, et al.
    Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem. 2012; 287: 40140–9.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    2. Wei Q,
    3. Guo P,
    4. Mu K,
    5. Zhang Y,
    6. Zhao W,
    7. Huai W, et al.
    Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome. Lab Invest. 2015; 95: 804–16.
    OpenUrlCrossRefPubMed
  52. 52.↵
    2. Chang-Lee SN,
    3. Hsu HH,
    4. Shibu MA,
    5. Ho TJ,
    6. Tsai CH,
    7. Chen MC, et al.
    E2/ERβ inhibits PPARα to regulate cell-proliferation and enhance apoptosis in Hep3B-hepatocellular carcinoma. Pathol Oncol Res. 2017; 23: 477–85.
    OpenUrlPubMed
  53. 53.↵
    2. Wei T,
    3. Chen W,
    4. Wen L,
    5. Zhang J,
    6. Zhang Q,
    7. Yang J, et al.
    G protein-coupled estrogen receptor deficiency accelerates liver tumorigenesis by enhancing inflammation and fibrosis. Cancer Lett. 2016; 382: 195–202.
    OpenUrlCrossRefPubMed
  54. 54.↵
    2. Qiu YA,
    3. Xiong J,
    4. Fu Q,
    5. Dong Y,
    6. Liu M,
    7. Peng M, et al.
    GPER-induced ERK signaling decreases cell viability of hepatocellular carcinoma. Front Oncol. 2021; 11: 638171.
  55. 55.↵
    2. Baldissera VD,
    3. Alves AF,
    4. Almeida S,
    5. Porawski M,
    6. Giovenardi M.
    Hepatocellular carcinoma and estrogen receptors: polymorphisms and isoforms relations and implications. Med Hypotheses. 2016; 86: 67–70.
    OpenUrlPubMed
  56. 56.↵
    2. Chen J,
    3. Chen L,
    4. Lu T,
    5. Xie Y,
    6. Li C,
    7. Jia Z, et al.
    ERalpha36 is an effective target of epigallocatechin-3-gallate in hepatocellular carcinoma. Int J Clin Exp Pathol. 2019; 12: 3222–34.
    OpenUrlPubMed
  57. 57.↵
    2. Lee E,
    3. Horn-Ross PL,
    4. Rull RP,
    5. Neuhausen SL,
    6. Anton-Culver H,
    7. Ursin G, et al.
    Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS. Am J Epidemiol. 2013; 178: 1403–13.
    OpenUrlCrossRefPubMedWeb of Science
  58. 58.↵
    2. Andersson G,
    3. Borgquist S,
    4. Jirström K.
    Hormonal factors and pancreatic cancer risk in women: the Malmö diet and cancer study. Int J Cancer. 2018; 143: 52–62.
    OpenUrlCrossRefPubMed
  59. 59.↵
    2. Akula SM,
    3. Candido S,
    4. Abrams SL,
    5. Steelman LS,
    6. Lertpiriyapong K,
    7. Cocco L, et al.
    Abilities of β-estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. Adv Biol Regul. 2020; 75: 100672.
  60. 60.↵
    2. Seeliger H,
    3. Pozios I,
    4. Assmann G,
    5. Zhao Y,
    6. Müller MH,
    7. Knösel T, et al.
    Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma. BMC Cancer. 2018; 18: 1049.
    OpenUrlPubMed
  61. 61.↵
    2. Pozios I,
    3. Knösel T,
    4. Zhao Y,
    5. Assmann G,
    6. Pozios I,
    7. Müller MH, et al.
    Expression of phosphorylated estrogen receptor beta is an independent negative prognostic factor for pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol. 2018; 144: 1887–97.
    OpenUrlPubMed
  62. 62.↵
    2. Iwao K,
    3. Miyoshi Y,
    4. Ooka M,
    5. Ishikawa O,
    6. Ohigashi H,
    7. Kasugai T, et al.
    Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in human pancreatic cancers by real-time polymerase chain reaction. Cancer Lett. 2001; 170: 91–7.
    OpenUrlCrossRefPubMed
  63. 63.↵
    2. Chan KS,
    3. Ho BCS,
    4. Shelat VG.
    A pilot study of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC). Transl Gastroenterol Hepatol. 2021; 6: 9.
    OpenUrlPubMed
  64. 64.↵
    2. Natale CA,
    3. Li J,
    4. Pitarresi JR,
    5. Norgard RJ,
    6. Dentchev T,
    7. Capell BC, et al.
    Pharmacologic activation of the G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma. Cell Mol Gastroenterol Hepatol. 2020; 10: 868–80.e1.
    OpenUrlPubMed
  65. 65.↵
    2. Rice A,
    3. Cortes E,
    4. Lachowski D,
    5. Oertle P,
    6. Matellan C,
    7. Thorpe SD, et al.
    GPER activation inhibits cancer cell mechanotransduction and basement membrane invasion via RhoA. Cancers (Basel). 2020; 12: 289.
    OpenUrlPubMed
  66. 66.↵
    2. Lim HK,
    3. Kwon HJ,
    4. Lee GS,
    5. Moon JH,
    6. Jung J.
    Chrysin-induced G protein-coupled estrogen receptor activation suppresses pancreatic cancer. Int J Mol Sci. 2022; 23: 9673.
    OpenUrlPubMed
  67. 67.↵
    2. Bockorny B,
    3. Semenisty V,
    4. Macarulla T,
    5. Borazanci E,
    6. Wolpin BM,
    7. Stemmer SM, et al.
    BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med. 2020; 26: 878–85.
    OpenUrlPubMed
  68. 68.↵
    2. Liot S,
    3. Balas J,
    4. Aubert A,
    5. Prigent L,
    6. Mercier-Gouy P,
    7. Verrier B, et al.
    Stroma involvement in pancreatic ductal adenocarcinoma: an overview focusing on extracellular matrix proteins. Front Immunol. 2021; 12: 612271.
  69. 69.↵
    2. Cortes E,
    3. Lachowski D,
    4. Okada-Hatakeyama M,
    5. Varjosalo MT,
    6. Del Río Hernández AE,
    7. Robinson B, et al.
    Tamoxifen mechanically reprograms the tumor microenvironment via HIF-1A and reduces cancer cell survival. EMBO Rep. 2019; 20: e46557.
  70. 70.↵
    2. Cortes E,
    3. Sarper M,
    4. Robinson B,
    5. Lachowski D,
    6. Chronopoulos A,
    7. Thorpe SD, et al.
    GPER is a mechanoregulator of pancreatic stellate cells and the tumor microenvironment. EMBO Rep. 2019; 20: e46556.
  71. 71.↵
    2. Dooling LJ,
    3. Discher DE.
    Inhibiting tumor fibrosis and actomyosin through GPCR activation. Trends Cancer. 2019; 5: 197–99.
    OpenUrlPubMed
  72. 72.↵
    2. Wang BJ,
    3. Zhang B,
    4. Yan SS,
    5. Li ZC,
    6. Jiang T,
    7. Hua CJ, et al.
    Hormonal and reproductive factors and risk of esophageal cancer in women: a meta-analysis. Dis Esophagus. 2016; 29: 448–54.
    OpenUrlCrossRefPubMed
  73. 73.↵
    2. Zhang D,
    3. Ku J,
    4. Liu R,
    5. Wu H,
    6. Liang G,
    7. Wei Y, et al.
    Characterization of serum estradiol level and tissue estrogen receptor immunostaining with clinical response and reproductive factor changes in Chinese female patients with esophageal squamous cell carcinoma. Biomed Pharmacother. 2017; 93: 879–84.
    OpenUrlPubMed
  74. 74.↵
    2. Ueo H,
    3. Matsuoka H,
    4. Sugimachi K,
    5. Kuwano H,
    6. Mori M,
    7. Akiyoshi T.
    Inhibitory effects of estrogen on the growth of a human esophageal carcinoma cell line. Cancer Res. 1990; 50: 7212–5.
    OpenUrlAbstract/FREE Full Text
  75. 75.↵
    2. Wang C,
    3. Wang P,
    4. Liu JC,
    5. Zhao ZA,
    6. Guo R,
    7. Li Y, et al.
    Interaction of estradiol and endoplasmic reticulum stress in the development of esophageal carcinoma. Front Endocrinol (Lausanne). 2020; 11: 410.
    OpenUrlPubMed
  76. 76.↵
    2. Zhang Z,
    3. He Q,
    4. Fu S,
    5. Zheng Z.
    Estrogen receptors in regulating cell proliferation of esophageal squamous cell carcinoma: involvement of intracellular Ca2+ signaling. Pathol Oncol Res. 2017; 23: 329–34.
    OpenUrlPubMed
  77. 77.↵
    2. Zuguchi M,
    3. Miki Y,
    4. Onodera Y,
    5. Fujishima F,
    6. Takeyama D,
    7. Okamoto H, et al.
    Estrogen receptor α and β in esophageal squamous cell carcinoma. Cancer Sci. 2012; 103: 1348–55.
    OpenUrlCrossRefPubMed
  78. 78.↵
    2. Dong J,
    3. Jiang SW,
    4. Niu Y,
    5. Chen L,
    6. Liu S,
    7. Ma T, et al.
    Expression of estrogen receptor α and β in esophageal squamous cell carcinoma. Oncol Rep. 2013; 30: 2771–6.
    OpenUrlPubMed
  79. 79.↵
    2. Nozoe T,
    3. Oyama T,
    4. Takenoyama M,
    5. Hanagiri T,
    6. Sugio K,
    7. Yasumoto K.
    Significance of immunohistochemical expression of estrogen receptors alpha and beta in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2007; 13: 4046–50.
    OpenUrlAbstract/FREE Full Text
  80. 80.↵
    2. Yang S,
    3. Deng L,
    4. Lai Y,
    5. Liu Z.
    Over expression of GPR30, indicating poor prognosis and promoting proliferation, upregulates Beclin-1 expression via p38MAPK signaling in esophageal squamous cell carcinoma progression. Int J Clin Exp Pathol. 2018; 11: 3426–35.
    OpenUrlPubMed
  81. 81.↵
    2. Thrift AP.
    Barrett’s esophagus and esophageal adenocarcinoma: how common are they really? Dig Dis Sci. 2018; 63: 1988–96.
    OpenUrlCrossRefPubMed
  82. 82.↵
    2. Mathieu LN,
    3. Kanarek NF,
    4. Tsai HL,
    5. Rudin CM,
    6. Brock MV.
    Age and sex differences in the incidence of esophageal adenocarcinoma: results from the surveillance, epidemiology, and end results (SEER) registry (1973-2008). Dis Esophagus. 2014; 27: 757–63.
    OpenUrlCrossRefPubMed
  83. 83.↵
    2. Shaheen N,
    3. Ransohoff DF.
    Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA. 2002; 287: 1972–81.
    OpenUrlCrossRefPubMedWeb of Science
  84. 84.↵
    2. Kang A,
    3. Khokale R,
    4. Awolumate OJ,
    5. Fayyaz H,
    6. Cancarevic I.
    Is estrogen a curse or a blessing in disguise? Role of estrogen in gastroesophageal reflux disease. Cureus. 2020; 12: e11180.
  85. 85.↵
    2. Ashcroft GS,
    3. Mills SJ,
    4. Lei K,
    5. Gibbons L,
    6. Jeong MJ,
    7. Taniguchi M, et al.
    Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. J Clin Invest. 2003; 111: 1309–18.
    OpenUrlCrossRefPubMedWeb of Science
  86. 86.↵
    2. Masaka T,
    3. Iijima K,
    4. Endo H,
    5. Asanuma K,
    6. Ara N,
    7. Ishiyama F, et al.
    Gender differences in oesophageal mucosal injury in a reflux oesophagitis model of rats. Gut. 2013; 62: 6–14.
    OpenUrlAbstract/FREE Full Text
  87. 87.↵
    2. Honda J,
    3. Iijima K,
    4. Asanuma K,
    5. Ara N,
    6. Shiroki T,
    7. Kondo Y, et al.
    Estrogen enhances esophageal barrier function by potentiating occludin expression. Dig Dis Sci. 2016; 61: 1028–38.
    OpenUrlPubMed
  88. 88.↵
    2. Asanuma K,
    3. Iijima K,
    4. Shimosegawa T.
    Gender difference in gastro-esophageal reflux diseases. World J Gastroenterol. 2016; 22: 1800–10.
    OpenUrlPubMed
  89. 89.↵
    2. Menon S,
    3. Nightingale P,
    4. Trudgill N.
    Is hormone replacement therapy in post-menopausal women associated with a reduced risk of oesophageal cancer? United European Gastroenterol J. 2014; 2: 374–82.
    OpenUrlCrossRefPubMed
  90. 90.↵
    2. Lagergren K,
    3. Lagergren J,
    4. Brusselaers N.
    Hormone replacement therapy and oral contraceptives and risk of oesophageal adenocarcinoma: a systematic review and meta-analysis. Int J Cancer. 2014; 135: 2183–90.
    OpenUrlCrossRefPubMed
  91. 91.↵
    2. Brusselaers N,
    3. Maret-Ouda J,
    4. Konings P,
    5. El-Serag HB,
    6. Lagergren J.
    Menopausal hormone therapy and the risk of esophageal and gastric cancer. Int J Cancer. 2017; 140: 1693–99.
    OpenUrlPubMed
  92. 92.↵
    2. Petrick JL,
    3. Hyland PL,
    4. Caron P,
    5. Falk RT,
    6. Pfeiffer RM,
    7. Dawsey SM, et al.
    Associations between prediagnostic concentrations of circulating sex steroid hormones and esophageal/gastric cardia adenocarcinoma among men. J Natl Cancer Inst. 2019; 111: 34–41.
    OpenUrlPubMed
  93. 93.↵
    2. McMenamin ÚC,
    3. Trainor J,
    4. Coleman HG,
    5. McManus DT,
    6. McQuaid S,
    7. Bingham V, et al.
    Sex hormone receptor expression and survival in esophageal adenocarcinoma: a prospective cohort study. Oncotarget. 2018; 9: 35300–12.
    OpenUrlPubMed
  94. 94.↵
    2. Due SL,
    3. Watson DI,
    4. Bastian I,
    5. Ding GQ,
    6. Sukocheva OA,
    7. Astill DS, et al.
    Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells. Surg Oncol. 2016; 25: 269–77.
    OpenUrlPubMed
  95. 95.↵
    2. Al-Khyatt W,
    3. Tufarelli C,
    4. Khan R,
    5. Iftikhar SY.
    Selective oestrogen receptor antagonists inhibit oesophageal cancer cell proliferation in vitro. BMC Cancer. 2018; 18: 121.
    OpenUrlPubMed
  96. 96.↵
    2. Akgun H,
    3. Lechago J,
    4. Younes M.
    Estrogen receptor-beta is expressed in Barrett’s metaplasia and associated adenocarcinoma of the esophagus. Anticancer Res. 2002; 22: 1459–61.
    OpenUrlPubMed
  97. 97.↵
    2. Sukocheva OA,
    3. Wee C,
    4. Ansar A,
    5. Hussey DJ,
    6. Watson DI.
    Effect of estrogen on growth and apoptosis in esophageal adenocarcinoma cells. Dis Esophagus. 2013; 26: 628–35.
    OpenUrlCrossRefPubMed
  98. 98.↵
    2. Due SL,
    3. Watson DI,
    4. Bastian I,
    5. Eichelmann AK,
    6. Hussey DJ.
    Oestrogen receptor isoforms may represent a therapeutic target in oesophageal adenocarcinoma. Cancers (Basel). 2022; 14: 1891.
    OpenUrlPubMed
  99. 99.↵
    2. Rawla P,
    3. Barsouk A.
    Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019; 14: 26–38.
    OpenUrlCrossRefPubMed
  100. 100.↵
    2. Jang YC,
    3. Leung CY,
    4. Huang HL.
    Association of hormone replacement therapy with risk of gastric cancer: a systematic review and meta-analysis. Sci Rep. 2022; 12: 12997.
  101. 101.↵
    2. Furukawa H,
    3. Iwanaga T,
    4. Koyama H,
    5. Taniguchi H.
    Effect of sex hormones on the experimental induction of cancer in rat stomach – a preliminary study. Digestion. 1982; 23: 151–5.
    OpenUrlPubMedWeb of Science
  102. 102.↵
    2. Xu CY,
    3. Guo JL,
    4. Jiang ZN,
    5. Xie SD,
    6. Shen JG,
    7. Shen JY, et al.
    Prognostic role of estrogen receptor alpha and estrogen receptor beta in gastric cancer. Ann Surg Oncol. 2010; 17: 2503–9.
    OpenUrlCrossRefPubMed
  103. 103.↵
    2. Zhou J,
    3. Teng R,
    4. Xu C,
    5. Wang Q,
    6. Guo J,
    7. Xu C, et al.
    Overexpression of ERα inhibits proliferation and invasion of MKN28 gastric cancer cells by suppressing β-catenin. Oncol Rep. 2013; 30: 1622–30.
    OpenUrlPubMed
  104. 104.↵
    2. Deng H,
    3. Huang X,
    4. Fan J,
    5. Wang L,
    6. Xia Q,
    7. Yang X, et al.
    A variant of estrogen receptor-alpha, ER-alpha36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis. Oncol Rep. 2010; 24: 171–6.
    OpenUrlPubMed
  105. 105.
    2. Fu Z,
    3. Deng H,
    4. Wang X,
    5. Yang X,
    6. Wang Z,
    7. Liu L.
    Involvement of ER-α36 in the malignant growth of gastric carcinoma cells is associated with GRP94 overexpression. Histopathology. 2013; 63: 325–33.
    OpenUrlPubMed
  106. 106.↵
    2. Wang X,
    3. Yuan C,
    4. Jin Y,
    5. Huang H,
    6. Sheng X,
    7. Wei W, et al.
    ER-α36 mediates gastric cancer cell invasion. Int J Clin Exp Pathol. 2020; 13: 1550–59.
    OpenUrlPubMed
  107. 107.↵
    2. Ryu WS,
    3. Kim JH,
    4. Jang YJ,
    5. Park SS,
    6. Um JW,
    7. Park SH, et al.
    Expression of estrogen receptors in gastric cancer and their clinical significance. J Surg Oncol. 2012; 106: 456–61.
    OpenUrlCrossRefPubMed
  108. 108.↵
    2. Tian S,
    3. Zhan N,
    4. Li R,
    5. Dong W.
    Downregulation of G protein-coupled estrogen receptor (GPER) is associated with reduced prognosis in patients with gastric cancer. Med Sci Monit. 2019; 25: 3115–26.
    OpenUrlPubMed
  109. 109.↵
    2. Lee SJ,
    3. Kim TW,
    4. Park GL,
    5. Hwang YS,
    6. Cho HJ,
    7. Kim JT, et al.
    G protein-coupled estrogen receptor-1 agonist induces chemotherapeutic effect via ER stress signaling in gastric cancer. BMB Rep. 2019; 52: 647–52.
    OpenUrlPubMed
  110. 110.↵
    2. Abancens M,
    3. Bustos V,
    4. Harvey H,
    5. McBryan J,
    6. Harvey BJ.
    Sexual dimorphism in colon cancer. Front Oncol. 2020; 10: 607909.
  111. 111.↵
    2. Schmuck R,
    3. Gerken M,
    4. Teegen EM,
    5. Krebs I,
    6. Klinkhammer-Schalke M,
    7. Aigner F, et al.
    Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients. Langenbecks Arch Surg. 2020; 405: 71–80.
    OpenUrlPubMed
  112. 112.↵
    2. Labadie JD,
    3. Harrison TA,
    4. Banbury B,
    5. Amtay EL,
    6. Bernd S,
    7. Brenner H, et al.
    Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes and tumor location. JNCI Cancer Spectr. 2020; 4: pkaa042.
  113. 113.↵
    2. Xu L,
    3. Li L,
    4. Xu D,
    5. Qiu J,
    6. Feng Q,
    7. Wen T, et al.
    Hormone replacement therapy in relation to the risk of colorectal cancer in women by BMI: a multicentre study with propensity score matching. Int J Clin Oncol. 2022; 27: 765–73.
    OpenUrlPubMed
  114. 114.↵
    2. Nüssler NC,
    3. Reinbacher K,
    4. Shanny N,
    5. Schirmeier A,
    6. Glanemann M,
    7. Neuhaus P, et al.
    Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. Gend Med. 2008; 5: 209–17.
    OpenUrlCrossRefPubMed
  115. 115.↵
    2. Rudolph A,
    3. Toth C,
    4. Hoffmeister M,
    5. Roth W,
    6. Herpel E,
    7. Jansen L, et al.
    Expression of oestrogen receptor β and prognosis of colorectal cancer. Br J Cancer. 2012; 107: 831–9.
    OpenUrlCrossRefPubMedWeb of Science
  116. 116.↵
    2. Topi G,
    3. Ghatak S,
    4. Satapathy SR,
    5. Ehrnström R,
    6. Lydrup ML,
    7. Sjölander A.
    Combined estrogen alpha and beta receptor expression has a prognostic significance for colorectal cancer patients. Front Med (Lausanne). 2022; 9: 739620.
  117. 117.↵
    2. Di Leo A,
    3. Barone M,
    4. Maiorano E,
    5. Tanzi S,
    6. Piscitelli D,
    7. Marangi S, et al.
    ER-beta expression in large bowel adenomas: implications in colon carcinogenesis. Dig Liver Dis. 2008; 40: 260–6.
    OpenUrlCrossRefPubMed
  118. 118.↵
    2. Principi M,
    3. Scavo MP,
    4. Piscitelli D,
    5. Villanacci V,
    6. Lovero R,
    7. Losurdo G, et al.
    The sharp decline of beta estrogen receptors expression in long-lasting ulcerative-associated carcinoma. Scand J Gastroenterol. 2015; 50: 1002–10.
    OpenUrlPubMed
  119. 119.↵
    2. Stevanato Filho PR,
    3. Aguiar Júnior S,
    4. Begnami MD,
    5. Ferreira FO,
    6. Nakagawa WT,
    7. Spencer R, et al.
    Estrogen receptor β as a prognostic marker of tumor progression in colorectal cancer with familial adenomatous polyposis and sporadic polyps. Pathol Oncol Res. 2018; 24: 533–40.
    OpenUrlCrossRefPubMed
  120. 120.↵
    2. Hartman J,
    3. Edvardsson K,
    4. Lindberg K,
    5. Zhao C,
    6. Williams C,
    7. Ström A, et al.
    Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res. 2009; 69: 6100–6.
    OpenUrlAbstract/FREE Full Text
  121. 121.↵
    2. Martineti V,
    3. Picariello L,
    4. Tognarini I,
    5. Carbonell Sala S,
    6. Gozzini A,
    7. Azzari C, et al.
    ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr Relat Cancer. 2005; 12: 455–69.
    OpenUrlAbstract/FREE Full Text
  122. 122.↵
    2. Indukuri R,
    3. Hases L,
    4. Archer A,
    5. Williams C.
    Estrogen receptor beta influences the inflammatory p65 cistrome in colon cancer cells. Front Endocrinol (Lausanne). 2021; 12: 650625.
  123. 123.↵
    2. Giroux V,
    3. Bernatchez G,
    4. Carrier JC.
    Chemopreventive effect of ERβ-Selective agonist on intestinal tumorigenesis in ApcMin/+ mice. Mol Carcinog. 2011; 50: 359–69.
    OpenUrlCrossRefPubMed
  124. 124.↵
    2. Son HJ,
    3. Sohn SH,
    4. Kim N,
    5. Lee HN,
    6. Lee SM,
    7. Nam RH, et al.
    Effect of estradiol in an azoxymethane/dextran sulfate sodium-treated mouse model of colorectal cancer: implication for sex difference in colorectal cancer development. Cancer Res Treat. 2019; 51: 632–48.
    OpenUrlPubMed
  125. 125.↵
    2. Song CH,
    3. Kim N,
    4. Lee SM,
    5. Nam RH,
    6. Choi SI,
    7. Kang SR, et al.
    Effects of 17β-estradiol on colorectal cancer development after azoxymethane/dextran sulfate sodium treatment of ovariectomized mice. Biochem Pharmacol. 2019; 164: 139–51.
    OpenUrlPubMed
  126. 126.↵
    2. Song CH,
    3. Kim N,
    4. Hee Nam R,
    5. In Choi S,
    6. Hee Son J,
    7. Eun Yu J, et al.
    17β-Estradiol strongly inhibits azoxymethane/dextran sulfate sodium-induced colorectal cancer development in Nrf2 knockout male mice. Biochem Pharmacol. 2020; 182: 114279.
  127. 127.↵
    2. Qi W,
    3. Weber CR,
    4. Wasland K,
    5. Savkovic SD.
    Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity. BMC Cancer. 2011; 11: 219.
    OpenUrlCrossRefPubMed
  128. 128.↵
    2. Pintova S,
    3. Dharmupari S,
    4. Moshier E,
    5. Zubizarreta N,
    6. Ang C,
    7. Holcombe RF.
    Genistein combined with FOLFOX or FOLFOX-bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. Cancer Chemother Pharmacol. 2019; 84: 591–98.
    OpenUrlPubMed
  129. 129.↵
    2. Zhao X,
    3. Li X,
    4. Ren Q,
    5. Tian J,
    6. Chen J.
    Calycosin induces apoptosis in colorectal cancer cells, through modulating the ERbeta/MiR-95 and IGF-1R, PI3K/Akt signaling pathways. Gene. 2016; 591: 123–28.
    OpenUrlPubMed
  130. 130.↵
    2. Calabrese C,
    3. Pratico C,
    4. Calafiore A,
    5. Coscia M,
    6. Gentilini L,
    7. Poggioli G, et al.
    Eviendep® reduces number and size of duodenal polyps in familial adenomatous polyposis patients with ileal pouch-anal anastomosis. World J Gastroenterol. 2013; 19: 5671–7.
    OpenUrlCrossRefPubMed
  131. 131.↵
    2. Jacenik D,
    3. Krajewska WM.
    Significance of G protein-coupled estrogen receptor in the pathophysiology of irritable bowel syndrome, inflammatory bowel diseases and colorectal cancer. Front Endocrinol (Lausanne). 2020; 11: 390.
    OpenUrlPubMed
  132. 132.↵
    2. Prossnitz ER,
    3. Barton M.
    The G protein-coupled oestrogen receptor GPER in health and disease: an update. Nat Rev Endocrinol. 2023; 19: 407–24.
    OpenUrlPubMed
  133. 133.↵
    2. Liu Q,
    3. Chen Z,
    4. Jiang G,
    5. Zhou Y,
    6. Yang X,
    7. Huang H, et al.
    Epigenetic down regulation of G protein-coupled estrogen receptor (GPER) functions as a tumor suppressor in colorectal cancer. Mol Cancer. 2017; 16: 87.
    OpenUrlCrossRefPubMed
  134. 134.↵
    2. Bustos V,
    3. Nolan Á M,
    4. Nijhuis A,
    5. Harvey H,
    6. Parker A,
    7. Poulsom R, et al.
    GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions. Oncotarget. 2017; 8: 84258–75.
    OpenUrlCrossRefPubMed
  135. 135.↵
    2. Kim IS.
    Current perspectives on the beneficial effects of soybean isoflavones and their metabolites for humans. Antioxidants (Basel). 2021; 10: 1064.
    OpenUrlPubMed
  136. 136.↵
    2. Zhou Y,
    3. Li Y,
    4. Zhou T,
    5. Zheng J,
    6. Li S,
    7. Li HB.
    Dietary natural products for prevention and treatment of liver cancer. Nutrients. 2016; 8: 156.
    OpenUrlPubMed
  137. 137.
    2. Lu D,
    3. Pan C,
    4. Ye C,
    5. Duan H,
    6. Xu F,
    7. Yin L, et al.
    Meta-analysis of soy consumption and gastrointestinal cancer risk. Sci Rep. 2017; 7: 4048.
    OpenUrlPubMed
  138. 138.↵
    2. Fan Y,
    3. Wang M,
    4. Li Z,
    5. Jiang H,
    6. Shi J,
    7. Shi X, et al.
    Intake of soy, soy isoflavones and soy protein and risk of cancer incidence and mortality. Front Nutr. 2022; 9: 847421.
  139. 139.↵
    2. Patel HK,
    3. Bihani T.
    Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther. 2018; 186: 1–24.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords